TRIESENCE Drug Patent Profile
✉ Email this page to a colleague
When do Triesence patents expire, and when can generic versions of Triesence launch?
Triesence is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug.
This drug has twenty-five patent family members in twenty-one countries.
The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Triesence
A generic version of TRIESENCE was approved as triamcinolone acetonide by TARO on October 1st, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRIESENCE?
- What are the global sales for TRIESENCE?
- What is Average Wholesale Price for TRIESENCE?
Summary for TRIESENCE
| International Patents: | 25 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 82 |
| Clinical Trials: | 10 |
| Patent Applications: | 4,278 |
| Drug Prices: | Drug price information for TRIESENCE |
| What excipients (inactive ingredients) are in TRIESENCE? | TRIESENCE excipients list |
| DailyMed Link: | TRIESENCE at DailyMed |
Recent Clinical Trials for TRIESENCE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Oxular Limited | Phase 2 |
| Wake Forest University Health Sciences | Phase 4 |
| Bausch & Lomb Incorporated | N/A |
Pharmacology for TRIESENCE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for TRIESENCE
TRIESENCE is protected by three US patents.
Patents protecting TRIESENCE
Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: VISUALIZATION DURING VITRECTOMY PROCEDURES
Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF OPHTHALMIC DISORDERS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Harrow Eye | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRIESENCE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Harrow Eye | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRIESENCE
See the table below for patents covering TRIESENCE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 101959519 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | ⤷ Sign Up |
| Chile | 2009000573 | Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo. | ⤷ Sign Up |
| Australia | 2009223649 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
